Immune checkpoint inhibitors (ICI) targeting programmed cell death 1 (PD-1) or cytotoxic T lymphocyte-associated protein 4 (CTLA-4) are standard of care for advanced-stage melanoma and have considerably improved patient survival (2). This evidence concerns the gene PDCD1 and melanoma.